Condition: Refractory Chronic Cough · Sponsor: Trevi Therapeutics
The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.
This description comes directly from the study's public registry record.
Paula Buckley · (203) 304-2499 · Paula.Buckley@trevitherapeutics.com
Connie Crum
Always discuss trial participation with your own doctor first.
| BLC Clinical Research | Burlington, Canada | Recruiting |
| Diex Recherche - Quebec | Québec, Canada | Recruiting |
| Clinique Specialisee En Allergie De La Capitale | Québec, Canada | Recruiting |
| Centre D'Investigation Clinique Mauricie Inc (CIC Mauricie) | Trois-Rivières, Canada | Recruiting |
| Diex Recherche-Victoriaville | Victoriaville, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07671924